Komori
Earnings4893Noile-Immune Biotech Inc.Pharmaceuticals

Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)

In the first quarter, business revenue fell from ¥2 million in the same period of the previous year to zero, while the operating loss was ¥202 million and the quarterly net loss was ¥153 million, resulting in narrower losses. Subsidy income of ¥45 million also contributed to the reduction in the ordinary loss.

Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
39.544
¥ million (reduction in operating loss)
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAP
Net Sales0¥ million
Operating profit-202¥ million
Ordinary income-152¥ million
Net income attributable to owners of the parent-153¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share-¥3.54
Financial position at period-end
Total assets3,844¥ million
of which net assets 3,778 ¥ millionEquity ratio 98.1%vs. prior year-end +0.3pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Annual Dividend Forecast¥0 → ¥0(0.0%)
Factors Behind Changes in Business Performance

No business revenue was recorded, while an operating loss was recorded as development continued. However, the ordinary loss narrowed as a result of recording ¥45.000 million in subsidy income from Yamaguchi Prefecture and Ube City.

Disclosure regarding the going concern assumption

No applicable matters

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Depreciation and amortization¥0 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End43,301,765 Shares
Treasury Shares at Period-End125 Shares
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (standalone)
Period Covered1 January 2026–31 March 2026
Net Sales¥0 million
Operating profit¥-202 million
Ordinary income¥-152 million
Profit attributable to owners of the parent¥-153 million
Net income per share-¥3.54
Equity ratioEnd of the current fiscal period 98.1 / End of previous period 97.8
Total assets¥3,844 million
Net assets¥3,778 million
Annual Dividend Forecast¥0 → ¥0(0.0%)
Depreciation and amortization¥0 thousand
Disclosure regarding the going concern assumptionNo applicable matters
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNo
Issued Shares at Period-End43,301,765 Shares
Treasury Shares at Period-End125 Shares
Factors Behind Changes in Business PerformanceNo business revenue was recorded, while an operating loss was recorded as development continued. However, the ordinary loss narrowed as a result of recording ¥45.000 million in subsidy income from Yamaguchi Prefecture and Ube City.
Items this document does not state (17)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidationMaterial subsequent events

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although the Company recorded an operating loss as development continued, it recorded ¥45 million in subsidy income from Yamaguchi Prefecture and Ube City, resulting in narrower ordinary and quarterly net losses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Summary of Financial Results for the First Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated) | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori